Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
are the mainstay imaging modalities in evaluating the immunocompromised host with ARI, nuclear scintigraphy using gallium-67 (Ga-67) or Tc-99m diethylenetriamine penta acetate (DTPA) radiotracers have quite specific but rarely used indications in this setting. Ga-67 can be used to help diagnose Mycobacteriumavium intracellulare, Mycobacterium tuberculosis, and lymphoma based on increased radiotracer activity in hilar and mediastinal lymph nodes. However, this finding is nonspecific, and distinguishing between (...) . Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures
of the Gastrointestinal Tract VIII. Intra-abdominal Infections IX. Bone and Joint Infections X. Urinary Tract Infections XI. Genital Infections XII. Skin and Soft Tissue Infections XIII. Arthropod-Borne Infections XIV. Viral Syndromes XV. Blood and Tissue Parasite Infections EXECUTIVE SUMMARY INTRODUCTION Unlike other areas of the diagnostic laboratory, clinical microbiology is a science of interpretive judgment that is becoming more complex, not less. Even with the advent of laboratory automation and the integration (...) container, RT, 2 h Abbreviations: AFB, acid-fast bacilli; CDC, Centers for Disease Control and Prevention; EDTA, ethylenediaminetetraacetic acid; NAAT, nucleic acid amplification test; RT, room temperature. a Contact the microbiology laboratory regarding appropriate collection and transport devices and procedures as transport media such as Cary-Blair or parasite preservative transport for stool specimens, boric acid for urines, and specialized containers for Mycobacterium tuberculosis are often critical
and are found in high concentrations in blood and spleen recognize infected cells and respond by directly killing these cells secrete cytokines that activate macrophages to destroy phagocytosed microbes important in defense against intracellular microbes particularly viruses and intracellular bacteria such as L. monocytogenes. CELLULAR IMMUNE DYSFUNCTION Bacteria Listeria monocytogenes Salmonella sp. Mycobacterium tuberculosis Mycobacteriumavium-intracellulare Legionella sp. Nocardia sp. Fungi Cryptococcus (...) the respiratory or gastrointestinal tract. Immunoglobulin E (IgE), surface of mast cells and basophils responsible for immediate-type hypersensitivity reactions important in defense against helminthic pathogens. IgG widely distributed in tissues accounts for 75% of the total immunoglobulin mass. It crosses the placenta and provides fetal immunity during the first 6 months of life Congenital or acquired deficiencies of IgG lead to infection with encapsulated organisms Complement complex interaction of 30
resolution was fasterin the absence of cavitary lung disease. All studies on cough prevalence in Mycobacteriumaviumcomplex (MAC) lung disease, other nontuberculous mycobacterial infections, fungal lung disease, and paragonimiasis were of poor quality and were excluded from the evidence review. ABBREVIATIONS: ACF = active case ?nding; ART = antiretroviral therapy; CD4 = CD4-positive T lymphocytes; CHEST = American College of Chest Physicians; DOTS = Directly Observed Treatment, Short Course; GRADE (...) resistance, poor adherence, and/or drug malabsorption compared with results in other in- dividualswithpulmonaryTB.CoughiscommoninpatientswithlunginfectionsduetoMAC, other nontuberculous mycobacteria, fungal diseases, and paragonimiasis. CHEST2018;153(2):467-497 KEY WORDS: cough; evidence-based medicine; fungal infections; Mycobacteriumaviumcomplex; nontuberculous mycobacterial; paragonimiasis; TB Summary of Recommendations and Suggestions 1. For patients with cough in high TB prevalence countries
Evaluation of the GenoType Mycobacteria Direct for direct detection of Mycobacterium tuberculosis complex obtained from sputum samples. An increase in the prevalence of tuberculosis (TB) in recent years has accelerated the search for novel tools for the rapid diagnosis of TB infection. This study evaluated the GenoType Mycobacteria Direct (GTMD) assay (Hain Lifescience) for direct detection of the Mycobacterium tuberculosis complex (MTBC) from sputum samples and compared it with conventional (...) methods. The GTMD test is a commercial assay produced using strip techniques and works based on a nucleic acid sequence-based amplification technique. This test allows 23S rRNA amplification-based detection of MTBC, Mycobacteriumavium, Mycobacterium intracellulare, Mycobacterium kansasii and Mycobacterium malmoense directly from decontaminated clinical samples within 6 h. In the present study, 115 sputum samples were processed to detect acid-fast bacilli (AFB) using two microscopy methods (carbol
tests (NAATs) should be available with rapid turnaround times from specimen collection. Table 2. Essential Laboratory Tests for the Detection of Mycobacterium tuberculosis Test Time Required I. Nucleic acid amplification test, detection (NAAT -TB) 1 d II. Nucleic acid amplification test, resistance markers (NAAT -R) 1–2 d III. Acid-fast bacilli microscopy 1 d IV. Growth detection Liquid Solid Up to 6–8 wk (average 10–14 d) (average 3–4 wk) V. Identification of Mycobacterium tuberculosis complex (...) Health, Nashville, Tennessee, 14 Wisconsin State Laboratory of Hygiene, Madison, and 15 University of Arkansas for Medical Sciences, Little Rock Background. Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (tuber- culosis disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). Tuberculosis disease is a leading cause of infectious disease morbidity and mortality worldwide, yet many questions related to its
organisms including, but not limited to, Cryptosporidium , Cyclospora , Cystoisospora , microsporidia, Mycobacteriumaviumcomplex, and cytomegalovirus (strong, moderate). 13. Diagnostic testing is not recommended in most cases of uncomplicated traveler’s diarrhea unless treatment is indicated. Travelers with diarrhea lasting 14 days or longer should be evaluated for intestinal parasitic infections (strong, moderate). Testing for C. difficile should be performed in travelers treated with antimicrobial (...) Hemochromatosis or hemoglobinopathy Y. enterocolitica , Salmonella AIDS, immunosuppressive therapies Cryptosporidium , Cyclospora , Cystoisospora , microsporidia, Mycobacteriumavium –intercellulare complex, cytomegalovirus Anal-genital, oral-anal, or digital-anal contact Shigella , Salmonella , Campylobacter , E. histolytica , Giardia lamblia , Cryptosporidium as well as sexually transmitted infections Exposure or Condition Pathogen(s) Foodborne Foodborne outbreaks in hotels, cruise ships, resorts
species Rotavirus—South America, Asia, Africa Recent camping Giardia, Aeromonas, Cryptosporidium Recent antibiotics: Increase in C. difficile infection Daycare exposure: Rotavirus Exposure to raw seafood: Non Cholera Vibrio Anal-receptive sex—men who have sex with men: Shigella, Campylobacter, Salmonella HIV-positive status: Mycobacteriumavium-intracellular complex, microsporidia, CMV, Giardia Outbreaks: Cruise ships—norovirus Contaminated local water, food, products, restaurants; organism usually (...) work-up. What additional steps may be required? Usual bacterial suspects plus (don’t forget primary HIV induced diarrhea, HAART induced, and salmonella / vibrio!): Cytomegalovirus Cyclospora Cryptosporidium Isospora Mycobacteriumavium-intracellulare complex Giardia Workup: Stool examination & cultures C Diff toxins and salmonella PCR CMV and MAI if CD4+ count <200 Acid fast smear for Cryptosporidium, Cystoisospora, Isospora, and Cyclospora sigmoidoscopy *If above workup negative consider small
prophylaxis is indicated and is cost-effective. Prophylaxis is started for PCP when CD4+ counts are less than 200 cells/μL, for toxoplasmosis, when CD4+ counts are less than 100 cells/μL and, for Mycobacteriumaviumcomplex (MAC) infection, when CD4+ counts are less than 50 cells/μL (Table 124.2).  List 5 risk factors for HIV / AIDS Contact with semen, blood, vaginal secretions, and breast milk of viremic individuals These fluids must come into contact with damaged tissue / mucous membrane / entry (...) , spleen, or nodes), onset at age >1 mo Cytomegalovirus retinitis (with loss of vision) Encephalopathy, HIV related Herpes simplex: chronic ulcers (>1 mo duration) or bronchitis, pneumonitis, or esophagitis (onset at age >1 mo) Histoplasmosis, disseminated or extrapulmonary Isosporiasis, chronic intestinal (>1 mo duration) Lymphoma, Burkitt’s (or equivalent term) Kaposi’s sarcoma Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of brain Mycobacteriumaviumcomplex or Mycobacterium
, Department of Health; 2015. p. 5. Available from: http://ww2.health.wa.gov.au/~/media/Files/Corporate/gene ral%20documents/water/PDF/Guidelines-for-Float- Tanks.ashx. 16. Moraga-McHaley SA, Landen M, Krapfl H, Sewell CM. Hypersensitivity pneumonitis with Mycobacteriumaviumcomplex among spa workers. Int J Occup Environ Health. 2013 Jan-Mar;19(1):55-61. 17. U.S. Centers for Disease Control and Prevention. The Model Aquatic Health Code (MAHC): an all-inclusive model public swimming pool and spa code
Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Nontuberculous mycobacteria are mycobacteria, other than those in the Mycobacterium tuberculosis complex, and are commonly found in the environment. Nontuberculous mycobacteria species (most commonly Mycobacteriumaviumcomplex and Mycobacterium abscessus) are isolated from the respiratory tract of approximately 5% to 40% of individuals with cystic fibrosis; they can cause lung disease in people (...) evidence for the effectiveness of different antimicrobial treatment for nontuberculous mycobacteria lung disease in people with cystic fibrosis. Until such evidence becomes available, it is reasonable for clinicians to follow published clinical practice guidelines for the diagnosis and treatment of nodular or bronchiectatic pulmonary disease due to Mycobacteriumaviumcomplex or Mycobacterium abscessus in patients with cystic fibrosis.
application for Arikayce (amikacin) On 8 June 2016, Insmed Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Arikayce intended for the treatment of Mycobacteriumaviumcomplex (MAC) lung disease. What is Arikayce? Arikayce is an antibiotic containing the active substance amikacin. It was to be available as a suspension for inhalation. What was Arikayce expected to be used for? Arikayce (...) was expected to be used to treat adults with a lung infection caused by Mycobacteriumaviumcomplex (MAC), a group of bacteria commonly found in the environment, such as in soil and water. It was to be used in patients whose infection has persisted despite previous treatment. Arikayce was designated an ‘orphan medicine’ (a medicine to be used in rare diseases) on 8 April 2014 for treating infections caused by MAC and similar bacteria. Further information on the orphan designation can be found here. How
amplification test for the detection of Mycobacterium tuberculosis complex in patients with signs and symptoms consistent with active tuberculosis. Fee: To be advised MBS item number Nucleic acid amplification test for the detection of non-tuberculous mycobacteria species in patients with a compatible clinical disease. Fee: To be advised 7. Summary of Public Consultation Feedback/Consumer Issues No specific Consumer impact statement was provided in the assessment. 8. Mycoba The use an addit intende for who (...) patients with other specimen types such as HIV-positive with M. aviumcomplex (MAC) disease or patients with disseminated bacteraemia. NAAT testing identifies a complex of mycobacteria however, there are different NAAT tests for different types of mycobacteria. ESC considered that under certain circumstances for one patient for the same episode multiple NAAT tests may be required. ESC agreed that the proposed comparators were appropriate. However, ESC noted that culture is an imperfect reference
. The Xpert MTB/RIF assay on sputum is more cost-effective than clinical diagnosis. To our knowledge, no published comparative studies addressed whether the rate of cough resolution is a reliable determinant of the response to treatment or whether the rate of cough resolution was faster in the absence of cavitary lung disease. All studies on cough prevalence in Mycobacteriumaviumcomplex (MAC) lung disease, other nontuberculous mycobacterial infections, fungal lung disease, and paragonimiasis were
Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Nontuberculous mycobacteria are mycobacteria, other than those in the Mycobacterium tuberculosis complex, and are commonly found in the environment. Nontuberculous mycobacteria species (most commonly Mycobacteriumaviumcomplex and Mycobacterium abscessus) are isolated from the respiratory tract of approximately 5% to 20% of individuals with cystic fibrosis; they can cause lung disease in people (...) available, it is reasonable for clinicians to follow the American Thoracic Society guidelines for the diagnosis and treatment of nodular or bronchiectatic pulmonary disease due to Mycobacteriumaviumcomplex or Mycobacterium abscessus in patients with cystic fibrosis.
in October 2015. Update of Clinical Guideline 117 Tuberculosis- clinical diagnosis, and measures for its prevention and control, incorporating PH37 Tuberculosis - Hard to reach Groups. Topics included Diagnostic procedures, Infectious diseases, Mental health/ behavioural conditions, Public health and, Respiratory. M.TB is usually caused by an organism in the mycobacterium tuberculosis complex, usually mycobacterium tuberculosis (M.TB) or mycobacterium Bovis (M. Bovis). M.TB will now be referred to as TB (...) (Tuberculosis) in this document. There are other environmental or atypical mycobacterial species (for example, mycobacteriumavium or mycobacterium maimoense), which do not have the same degree of infectivity and are therefore not covered by this guideline. This guideline does not cover BCG vaccination, as this is not currently performed routinely within the Trust. If necessary, please refer to NICE guideline ( ); refer to GP or local TB team. Please also note that staff pre-employment screening
with IBD treated with anti-TNFa agents are at increased risk of developing NTM infections (77). It is unknown if pediatric patients with IBD receiving anti-TNFa therapy are similarly at increased risk of NTM infections and whether risk is impacted by anti-TNFa therapy. One case of systemic Mycobacteriumaviumcomplex (MAC) infection was reported in an 11-year-old girl with CD who presented with generalized lymphadenopathy after receipt of infliximab followed by adalimumab (96). Epidemiology. NTM (...) and Canadian pediatric (16,17) and adult position statements (18,19) provide some ID screening guidance, summarized in supplementary Table 1 (http://links.lww.com/MPG/ A637). In general, the adult literature, both in rheumatology and gastroenterology patients, recommends testing for Mycobacterium tuberculosis, hepatitis B, hepatitis C, and human immunodeficiency virus (HIV) before initiating anti-TNFa (19–21). There are, how- ever, no US consensus statements to guide practices for the screen- ing
% but with considerable variation between individual states (0–28%). The NTM species most commonly identified in individuals with CF from North America and Europe are the slow-growing Mycobacteriumaviumcomplex (MAC) (including M. avium , M. intracellulare and M. chimaera ), which can be found in up to 72% of NTM-positive sputum cultures, and the rapid-growing M. abscessus complex (MABSC) (comprising the subspecies M. abscessus subsp abscessus ( M. a. abscessus ), M. a. bolletii and M. a. massiliense , (the latter (...) are listed in with important side effects/toxicities described in . View this table: Table 2 Antibiotic-dosing regimens used to treat Mycobacteriumaviumcomplex and Mycobacterium abscessus complex pulmonary disease in cystic fibrosis View this table: Table 3 Important side effects/toxicities of antibiotics and advisable monitoring procedures for MAC and MABSC in CF Figure 2 Typical treatment schedules for individuals with CF with Mycobacterium abscessus or MAC pulmonary disease. (A) M. abscessus